Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Martha C Nason"'
Autor:
Michelle C Crank, Eleanor M P Wilson, Laura Novik, Mary E Enama, Cynthia S Hendel, Wenjuan Gu, Martha C Nason, Robert T Bailer, Gary J Nabel, Adrian B McDermott, John R Mascola, Richard A Koup, Julie E Ledgerwood, Barney S Graham, VRC012 Study Team
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0166393 (2016)
BACKGROUND:VRC 012 was a Phase I study of a prototype recombinant adenoviral-vector serotype-35 (rAd35) HIV vaccine, the precursor to two recently published clinical trials, HVTN 077 and 083. On the basis of prior evaluation of multiclade rAd5 HIV va
Externí odkaz:
https://doaj.org/article/60ff6ef8e2674931b3b78aadb15768ec
Autor:
Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91366 (2014)
Phase 1 evaluation of the VRC HIV DNA and rAd5 vaccines delivered intramuscularly (i.m.) supported proceeding to a Phase 2 b efficacy study. Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration.Si
Externí odkaz:
https://doaj.org/article/2bd1714b908f4c17889a993bf675d1ce
Autor:
Uzma N Sarwar, Laura Novik, Mary E Enama, Sarah A Plummer, Richard A Koup, Martha C Nason, Robert T Bailer, Adrian B McDermott, Mario Roederer, John R Mascola, Julie E Ledgerwood, Barney S Graham, VRC 015 study team
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106240 (2014)
Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine.Thirty-one adults, 18-5
Externí odkaz:
https://doaj.org/article/47b0305e6d714b118f267d172a9204d1
Autor:
Barney S Graham, Mary E Enama, Martha C Nason, Ingelise J Gordon, Sheila A Peel, Julie E Ledgerwood, Sarah A Plummer, John R Mascola, Robert T Bailer, Mario Roederer, Richard A Koup, Gary J Nabel, VRC 008 Study Team
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e59340 (2013)
DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.Forty adults, 18-50 yea
Externí odkaz:
https://doaj.org/article/3b852a8c202e41198b2ecf9667a79776
Autor:
Richard A Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha C Nason, Brenda D Larkin, Mary E Enama, Julie E Ledgerwood, Robert T Bailer, John R Mascola, Gary J Nabel, Barney S Graham, VRC 009 Study Team, VRC 010 Study Team
Publikováno v:
PLoS ONE, Vol 5, Iss 2, p e9015 (2010)
Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinic
Externí odkaz:
https://doaj.org/article/d38547ce8a244bc9a6f7395ca975d051
Autor:
Justin Doritchamou, Morten A. Nielsen, Arnaud Chêne, Nicola K. Viebig, Lynn E. Lambert, Adam F. Sander, Jean-Philippe Semblat, Sophia Hundt, Sachy Orr-Gonzalez, Christoph M. Janitzek, Alicia J. Spiegel, Stine B. Clemmensen, Marvin L. Thomas, Martha C. Nason, Maryonne Snow-Smith, Emma K. Barnafo, Joseph Shiloach, Beth B. Chen, Steven Nadakal, Kendrick Highsmith, Tarik Ouahes, Solomon Conteh, Ankur Sharma, Holly Torano, Brandi Butler, Karine Reiter, Kelly M. Rausch, Puthupparampil V. Scaria, Charles Anderson, David L. Narum, Ali Salanti, Michal Fried, Thor G. Theander, Benoit Gamain, Patrick E. Duffy
Placental malaria vaccines (PMV) are being developed to prevent severe sequelae of placental malaria (PM) in pregnant women and their offspring. The leading candidate vaccine antigen VAR2CSA mediates parasite binding to placental receptor chondroitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa1736597080d88b6541de9f5dd20cfc
https://doi.org/10.1101/2022.06.24.497389
https://doi.org/10.1101/2022.06.24.497389
Autor:
Matthew Gagne, Juan I. Moliva, Kathryn E. Foulds, Shayne F. Andrew, Barbara J. Flynn, Anne P. Werner, Danielle A. Wagner, I-Ting Teng, Bob C. Lin, Christopher Moore, Nazaire Jean-Baptiste, Robin Carroll, Stephanie L. Foster, Mit Patel, Madison Ellis, Venkata-Viswanadh Edara, Nahara Vargas Maldonado, Mahnaz Minai, Lauren McCormick, Christopher Cole Honeycutt, Bianca M. Nagata, Kevin W. Bock, Caitlyn N. M. Dulan, Jamilet Cordon, John-Paul M. Todd, Elizabeth McCarthy, Laurent Pessaint, Alex Van Ry, Brandon Narvaez, Daniel Valentin, Anthony Cook, Alan Dodson, Katelyn Steingrebe, Dillon R. Flebbe, Saule T. Nurmukhambetova, Sucheta Godbole, Amy R. Henry, Farida Laboune, Jesmine Roberts-Torres, Cynthia G. Lorang, Shivani Amin, Jessica Trost, Mursal Naisan, Manjula Basappa, Jacquelyn Willis, Lingshu Wang, Wei Shi, Nicole A. Doria-Rose, Adam S. Olia, Cuiping Liu, Darcy R. Harris, Andrea Carfi, John R. Mascola, Peter D. Kwong, Darin K. Edwards, Hanne Andersen, Mark G. Lewis, Kizzmekia S. Corbett, Martha C. Nason, Adrian B. McDermott, Mehul S. Suthar, Ian N. Moore, Mario Roederer, Nancy J. Sullivan, Daniel C. Douek, Robert A. Seder
SummarySARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would enhance immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf75ae434882f0dd8baa7a19d8b7db69
https://doi.org/10.1101/2022.02.03.479037
https://doi.org/10.1101/2022.02.03.479037
Autor:
Ann R, Falsey, Magdalena E, Sobieszczyk, Ian, Hirsch, Stephanie, Sproule, Merlin L, Robb, Lawrence, Corey, Kathleen M, Neuzil, William, Hahn, Julie, Hunt, Mark J, Mulligan, Charlene, McEvoy, Edwin, DeJesus, Michael, Hassman, Susan J, Little, Barbara A, Pahud, Anna, Durbin, Paul, Pickrell, Eric S, Daar, Larry, Bush, Joel, Solis, Quito Osuna, Carr, Temitope, Oyedele, Susan, Buchbinder, Jessica, Cowden, Sergio L, Vargas, Alfredo, Guerreros Benavides, Robert, Call, Michael C, Keefer, Beth D, Kirkpatrick, John, Pullman, Tina, Tong, Margaret, Brewinski Isaacs, David, Benkeser, Holly E, Janes, Martha C, Nason, Justin A, Green, Elizabeth J, Kelly, Jill, Maaske, Nancy, Mueller, Kathryn, Shoemaker, Therese, Takas, Richard P, Marshall, Menelas N, Pangalos, Tonya, Villafana, Antonio, Gonzalez-Lopez, Barry S, Zingman
Publikováno v:
The New England Journal of Medicine
The New England journal of medicine, vol 385, iss 25
The New England journal of medicine, vol 385, iss 25
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been
Autor:
Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagne, Lilin Lai, Juan I. Moliva, Barbara Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds, Shayne F. Andrew, Dillon R. Flebbe, Evan Lamb, Saule T. Nurmukhambetova, Samantha J. Provost, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Alex Van Ry, Zackery Flinchbaugh, Timothy S. Johnston, Elham Bayat Mokhtari, Prakriti Mudvari, Amy R. Henry, Farida Laboune, Becky Chang, Maciel Porto, Jaclyn Wear, Gabriela S. Alvarado, Seyhan Boyoglu-Barnum, John-Paul M. Todd, Bridget Bart, Anthony Cook, Alan Dodson, Laurent Pessaint, Katelyn Steingrebe, Sayda Elbashir, Hanne Andersen, Kai Wu, Darin K. Edwards, Swagata Kar, Mark G. Lewis, Eli Bortiz, Ian N. Moore, Andrea Carfi, Mehul S. Suthar, Adrian McDermott, Mario Roederer, Martha C. Nason, Nancy J. Sullivan, Daniel C. Douek, Barney S. Graham, Robert A. Seder
Publikováno v:
bioRxiv
BackgroundVaccine efficacy against the B.1.351 variant following mRNA-1273 vaccination in humans has not been determined. Nonhuman primates (NHP) are a useful model for demonstrating whether mRNA-1273 mediates protection against B.1.351.MethodsNonhum
Autor:
Safia, Kuriakose, Kanal, Singh, Alice K, Pau, Eric, Daar, Rajesh, Gandhi, Pablo, Tebas, Laura, Evans, Roy M, Gulick, H Clifford, Lane, Henry, Masur, Judith A, Aberg, Adaora A, Adimora, Jason, Baker, Lisa Baumann, Kreuziger, Roger, Bedimo, Pamela S, Belperio, Stephen V, Cantrill, Craig M, Coopersmith, Susan L, Davis, Amy L, Dzierba, John J, Gallagher, David V, Glidden, Birgit, Grund, Erica J, Hardy, Carl, Hinkson, Brenna L, Hughes, Steven, Johnson, Marla J, Keller, Arthur Y, Kim, Jeffrey L, Lennox, Mitchell M, Levy, Jonathan Z, Li, Greg S, Martin, Susanna, Naggie, Andrew T, Pavia, Nitin, Seam, Steven Q, Simpson, Susan, Swindells, Phyllis, Tien, Alpana A, Waghmare, Kevin C, Wilson, Jinoos, Yazdany, Philip, Zachariah, Danielle M, Campbell, Carly, Harrison, Timothy, Burgess, Joseph, Francis, Virginia, Sheikh, Timothy M, Uyeki, Robert, Walker, John T, Brooks, Laura Bosque, Ortiz, Richard T, Davey, Laurie K, Doepel, Robert W, Eisinger, Alison, Han, Elizabeth S, Higgs, Martha C, Nason, Page, Crew, Andrea M, Lerner, Claire, Lund, Christopher, Worthington
Publikováno v:
Annals of Internal Medicine
In March 2020, the National Institutes of Health COVID-19 Treatment Guidelines Panel began developing evidence-based guidelines for the treatment of COVID-19. In this article, Panel members summarize some of the lessons learned from their first year